Tobias Welte (Hannover Medical School, Hannover, Germany) shares his expert clinical perspectives on the current challenges for diagnosis and treatment of nontuberculous mycobacteria (NTM) infections and how to optimise patient management moving forward.
Questions1. What unmet needs are currently encountered by patients with nontuberculous mycobacteria (NTM) lung disease? (0:12)
2. What are the main limitations for current NTM lung disease therapies? (1:38)
3. What is the most effective management plan following NTM diagnosis? (2:25)
4. What are the main limitations of current treatment options for patients with NTM? (3:19)
5. What are the emerging treatment options in NTM infection? (4:21)
Speaker disclosure: Tobias Welte has nothing to disclose in relation to this video interview.
Filmed at the European Respiratory Society (ERS) International Congress 2018, Paris, France, September 2018, supported by an unrestricted independent educational grant from Insmed.